FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Disclosed a monoclonal antibody, specific to syndecan-1, used as self-acting agent for the treatment of oncological diseases. Also disclosed a polynucleotide, coding circuit of the above antibody to syndecan-1, codon optimized for increasing of expression in cells of the producer. Polynucleotide can additionally contain a fragment, coding signal secretory sequence on the N-end, removable during secretion from the producer cells.
EFFECT: invention allows to produce efficient and safe anticancer agent and can be used in medicine for treating oncological diseases.
3 cl, 9 dwg, 2 ex
| Title |
Year |
Author |
Number |
| HUMANISED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 |
2013 |
- Dukhovlinov Il'Ja Vladimirovich
- Orlov Anton Iosifovich
- Balazovskij Mark Borisovich
- Spektor Dzhin Miron
|
RU2551235C2 |
| HUMANISED MONOCLONAL ANTIBODY SPECIFIC FOR LEGUMAIN |
2013 |
- Dukhovlinov Il'Ja Vladimirovich
- Orlov Anton Iosifovich
|
RU2574203C2 |
| CD138-TARGETED CELL AGENTS AND USING THEM |
2008 |
- Kraus,Ehl'Mar
- Brjukher,Kristof
- Delken,Benzhamin
- Germer,Mattias
- Tseng,Shteffen
- Osterrot,Frank
- Uehrek,Kristof
- Ajgner,Zil'Ke
- Shul'Ts,Gregor
|
RU2537265C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2013 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanyuj
- Selbi Mark Dzh.
- Chen Bin
- Kardarelli Zhozefin M.
|
RU2599417C2 |
| HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR PROGRAMMED CELL DEATH 1 (PD1) PROTEIN AND METHODS OF TREATING CANCER WITH USING ANTI-PD1 ANTIBODIES EITHER INDIVIDUALLY, OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2006 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanjuj
- Selbi Mark Dzh.
- Chehn' Bin
- Kardarelli Zhozefin M.
- Khuan Khajchun'
|
RU2494107C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2006 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanjuj
- Selbi Mark Dzh.
- Chehn' Bin
- Kardarelli Zhozefin M.
|
RU2406760C2 |
| ANTI-CD138 IMMUNOCONJUGATES AND USING THEM |
2008 |
- Kraus, Ehl'Mar
- Brjukher, Kristof
- Delken, Benzhamin
- Tseng, Shteffen
- Osterrot, Frank
- Uehrek, Kristof
- Ajgner, Zil'Ke
- Germer, Mattias
|
RU2547939C2 |
| ANTIBODIES SPECIFICALLY BINDING TYPE 1 RECEPTOR OF FIBROBLAST GROWTH FACTOR, ANTIBODIES APPLICATION FOR ONCOLOGICAL DISEASE TREATMENT, METHOD FOR ANTIBODIES PRODUCTION |
2015 |
|
RU2638457C2 |
| HUMAN MONOCLONAL ANTIBODIES TO THE PROTEIN OF PROGRAMMED DEATH 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2016 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanyuj
- Selbi Mark Dzh.
- Chen Bin
- Kardarelli Zhozefin M.
|
RU2732924C2 |
| METHOD FOR IMPROVING TARGETED ACTION OF CD138 EXPRESSING TUMOUR CELLS AND AGENTS TO THIS EFFECT |
2008 |
- Delken Benzhamin
- Uehrek Kristof
- Anderson Kennet
- Khidesima Teru
- Brjukher Kristof
|
RU2486203C2 |
